Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non Hodgkin Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    693 result(s) found for: Non Hodgkin Lymphoma. Displaying page 24 of 35.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    EudraCT Number: 2007-007756-34 Sponsor Protocol Number: CC-5013-MCL-001 Start Date*: 2009-02-06
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent lenalidomide (Revlimid ®) in patients with mantle cell NHL who have relapsed or progressed ...
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004356-30 Sponsor Protocol Number: PCYC-1145-LT Start Date*: 2020-03-11
    Sponsor Name:Pharmacyclics Switzerland GmbH, an AbbVie company
    Full Title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043515 Throat cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054695 Waldenstrom's macroglobulinemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042080 Stomach cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    20.0 100000004870 10018799 GVHD LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) GR (Completed) CZ (Trial now transitioned) DE (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001229-18 Sponsor Protocol Number: FIL_GAUDEALIS Start Date*: 2019-06-13
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study.
    Medical condition: recurrent / refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018866-21 Sponsor Protocol Number: Protocollo FLR/R 2510 Start Date*: 2010-07-19
    Sponsor Name:A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI
    Full Title: Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multi...
    Medical condition: RESISTANT FOLLICULAR NON HODGKIN LYNPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059433 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004977-12 Sponsor Protocol Number: MO19872 Start Date*: 2006-06-22
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy.
    Medical condition: Follicular non Hodgkin's Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000108-41 Sponsor Protocol Number: 062-HEM-102 Start Date*: 2019-02-06
    Sponsor Name:Sunesis Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies
    Medical condition: Male or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    20.1 100000004851 10047802 Waldenstrom's macroglobulinaemias HLT
    20.1 100000004864 10008948 Chronic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003993-30 Sponsor Protocol Number: IDP-121-1 Start Date*: 2022-07-01
    Sponsor Name:IDP Discovery Pharma S.L.
    Full Title: A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies
    Medical condition: Chronic lymphocytic leukemia (CLL) Diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS) High-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) High-grade B cel...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004851 10020068 High grade B-cell lymphomas Burkitt-like lymphoma HLT
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    21.1 100000004864 10020069 High grade B-cell lymphoma Burkitt-like lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004916-23 Sponsor Protocol Number: MORE Start Date*: 2014-04-28
    Sponsor Name:Ospedale San Raffaele
    Full Title: Monotherapy with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE)
    Medical condition: Splenic B-cell marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002483-31 Sponsor Protocol Number: UZBRU_VHH2_2 Start Date*: 2020-11-30
    Sponsor Name:UZ Brussel
    Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ...
    Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005010-30 Sponsor Protocol Number: KTE-C19-104 Start Date*: 2017-09-27
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) BE (Completed) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001039-29 Sponsor Protocol Number: GO40515 Start Date*: 2019-02-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ...
    Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005843-21 Sponsor Protocol Number: KT-US-982-5968 Start Date*: 2022-02-08
    Sponsor Name:KITE PHARMA INC.
    Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells
    Medical condition: B-cell malignancies and Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081514 Acute myeloid leukemia refractory LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006599 Burkitt's lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005537-11 Sponsor Protocol Number: NCT-2007-11-02-1004 Start Date*: 2011-07-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia
    Medical condition: Relapsed of progressive solid tumor, lymphoma, or leukemia in children and adolescents aage 3-18 years
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002208-41 Sponsor Protocol Number: CBKM120Z2402 Start Date*: 2013-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002227-42 Sponsor Protocol Number: UCL/17/0192 Start Date*: 2019-02-14
    Sponsor Name:University College London
    Full Title: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
    Medical condition: Advanced classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-020147-12 Sponsor Protocol Number: B1931008 Start Date*: 2011-02-16
    Sponsor Name:Pfizer Inc
    Full Title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTOR...
    Medical condition: Aggressive Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) ES (Completed) DE (Completed) GB (Completed) HU (Completed) LT (Completed) BG (Completed) BE (Completed) GR (Completed) NL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003888-23 Sponsor Protocol Number: 09/2005/2007 Start Date*: 2006-03-23
    Sponsor Name:University College London
    Full Title: A phase II multicentre trial of CVP, rituximab and gemcitabine for the treatment of patients with newly diagnosed diffuse large b-cell lymphoma considered unsuitable for r-chop chemotherapy
    Medical condition: Large B cell non-Hodgkin’s lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002003-17 Sponsor Protocol Number: 200427 Start Date*: 2005-07-18
    Sponsor Name:Rikshospitalet-Radiumhospitalet HF
    Full Title: High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patient...
    Medical condition: Mantle cell lymphoma is a non-Hodgkin lymphoma which is rare and holds a bad prognosis with no known curative therapies available. The lymphoma is most often disseminated at diagnosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Ongoing) DK (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001353-17 Sponsor Protocol Number: SPC2996-107 Start Date*: 2008-11-05
    Sponsor Name:Santaris Pharma A/S
    Full Title: A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA
    Medical condition: Follicular Lymphoma (FL); Lymphoplasmacytic (lymphoplasmacytoid) Lymphoma (LPL) / Waldenstrom’s macroglobulinemia (WM)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016905 Follicle centre lymphoma, follicular grade I, II, III recurrent LLT
    9.1 10025334 Lymphoplasmacytic type lymphoma (Kiel Classification) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006028-41 Sponsor Protocol Number: BER-PUM-01 Start Date*: 2022-02-21
    Sponsor Name:Pomorski Uniwersytet Medyczny w Szczecinie
    Full Title: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN
    Medical condition: Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 10:05:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA